InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced th...
Anova launches a free AI-enabled patient matching solution that uses proprietary algorithms to connect patients to 200,000+ open clinical trials with...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the EPO notified the...
Prilenia Therapeutics B.V. and Ferrer announced that the US Food and Drug Administration (FDA) has cleared the start of the pivotal, 500-patient, r...
After achieving early breakthroughs in materials development, in vitro nanoparticle stimulation and signal reading, Subsense secures additional $10 mil...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced that its next-generation TRK inhibitor, zurletrectinib (ICP-72...
Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the s...
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ta...
Ginkgo Bioworks announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health (ARPA-H...
Collaboration with Science Tokyo spinout underscores GlycoNex's integrated antibody development and manufacturing capabilities in support of first-in-cla...
-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...
Incyte announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class muta...
Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Intrepid Labs, the AI leader in pharmaceutical formulat...
BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involve...
© 2026 Biopharma Boardroom. All Rights Reserved.
